Morgan Stanley
MLNT

Morgan Stanley’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Morgan Stanley’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-10,412
Closed -$6K – 6924
2019
Q4 		$6K Buy
10,412
+6,940
+200% +$16.8K ﹤0.01% 6387
2019
Q3 		$14K Sell
3,472
-7,350
-68% -$26.5K ﹤0.01% 6119
2019
Q2 		$72K Buy
10,822
+4,906
+83% +$18.7K ﹤0.01% 5467
2019
Q1 		$21K Sell
5,916
-7,075
-54% -$38.4K ﹤0.01% 6004
2018
Q4 		$51K Sell
12,991
-14,853
-53% -$190K ﹤0.01% 5761
2018
Q3 		$550K Buy
27,844
+14,360
+106% +$363K ﹤0.01% 4948
2018
Q2 		$428K Sell
13,484
-784
-5% -$28.2K ﹤0.01% 5203
2018
Q1 		$527K Buy
14,268
+5,724
+67% +$376K ﹤0.01% 4970
2017
Q4 		$675K Buy
+8,544
New +$632K ﹤0.01% 4803

Morgan Stanley's MLNT Position: Q1 2020 in Review

Morgan Stanley sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2020, closing a stake of 10,412 shares — an estimated $6K sold.

Morgan Stanley first reported a position in MLNT in Q4 2017 and held it in 9 quarters. The position peaked at $675K in Q4 2017. 2 funds tracked by Wall St. Rank hold MLNT as of Q1 2020.

  • Morgan Stanley reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2020 after selling out during the quarter.
  • Morgan Stanley sold 10,412 Melinta Therapeutics, Inc. Common Stock shares in Q1 2020, an estimated $6K.
  • Morgan Stanley first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 9 quarters.
  • Morgan Stanley's Melinta Therapeutics, Inc. Common Stock position peaked at $675K in Q4 2017.
  • 2 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2020.

Based on Morgan Stanley's 13F filing for Q1 2020, filed 15 May 2020.